Last reviewed · How we verify
ZGN-440
At a glance
| Generic name | ZGN-440 |
|---|---|
| Also known as | Beloranib for subcutaneous injection |
| Sponsor | Zafgen, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (PHASE3)
- An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury (PHASE2)
- An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome (PHASE2)
- An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects (PHASE2)
- An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus (PHASE2)
- ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZGN-440 CI brief — competitive landscape report
- ZGN-440 updates RSS · CI watch RSS
- Zafgen, Inc. portfolio CI